Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis

Author:

Lehmann Lorenz H.12ORCID,Heckmann Markus B.1ORCID,Bailly Guillaume3,Finke Daniel1ORCID,Procureur Adrien3ORCID,Power John R.4ORCID,Stein Frederic13,Bretagne Marie3,Ederhy Stephane5ORCID,Fenioux Charlotte3,Hamwy Omar3,Funck-Brentano Elisa6ORCID,Romano Emanuela7,Pieroni Laurence8ORCID,Münster Jan P.19ORCID,Allenbach Yves10ORCID,Anquetil Céline10,Leonard-Louis Sarah11,Palaskas Nicolas L.12ORCID,Hayek Salim S.13ORCID,Katus Hugo A.1,Giannitsis Evangelos1ORCID,Frey Norbert1,Kaya Ziya1ORCID,Moslehi JavidORCID,Prifti Edi1415ORCID,Salem Joe-Elie3ORCID,Thuny Franck,Crusz Shanthini,Asnani Aarti,Karlstaedt Anja,Rocher Fanny,Paven Elise,Obeid Michel,Chan Wei Ting,Flint Danette L,Arangalage Dimitri,Courand Pierre-Yves,Nicol Martin,Cariou Eve,Tamura Yuichi,Florido Roberta,Francis Sanjeev,Leong Darryl,Piriou Nicolas,Akhter Nausheen,Shahneen Sandhu,Itzhaki Ben Zadok Osnat,Habib Manhal,Vachhani Pankit,Peretto Giovanni,Zhu Han,Laufer Perl Michal,Aras Mandar,Alexandre Joachim,Lenneman Carrie,Levenson Joshua,Deswal Anita,Zaha Vlad G.,Gaughan Elizabeth M,Ewer Steven,Johnson Douglas,Baldassarre Lauren A

Affiliation:

1. Department of Cardiology, Angiology, and Pneumology, Heidelberg University Hospital, German Centre for Cardiovascular Research DZHK, Heidelberg, Germany (L.H.L., M.B.H., D.F., F.S., J.P.M., H.A.K., E.G., N.F., Z.K.).

2. German Cancer Research Center (DKFZ), Heidelberg, Germany (L.H.L.).

3. Sorbonne Université, Assistance Publique-Hôpitaux de Paris, INSERM, Department of Pharmacology, UNICO-GRECO Cardio-oncology program, Pitié-salpétrière Hospital, Paris, France (G.B., A.P., F.S., M.B., C.F., O.H., J-E.S.).

4. University of California San Diego (J.R.P).

5. Sorbonne Université, Assistance Publique-Hôpitaux de Paris, INSERM, Department of Cardiology, UNICO-GRECO Cardio-oncology program, Saint-Antoine Hospital, Paris, France (S.E.).

6. Hopital Ambroise-Paré, Neuilly Sur Seine, France (E.F-B.).

7. Center for Cancer Immunotherapy, Department of Oncology, PSL Research University, Institut Curie, Paris, France (E.R.).

8. Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Biochimie- Hormonologie, Hôpital Tenon, Paris, France (L.P.).

9. Section of Cardio-Oncology and Immunology, Cardiovascular Research Institute, University of California San Francisco (J.P.M.).

10. Department of Internal Medicine (Y.A., C.A.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris, INSERM, Hôpital Pitié-Salpêtrière, France.

11. Neuropathology (S.L-L.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris, INSERM, Hôpital Pitié-Salpêtrière, France.

12. Department of Cardiology, University of Texas MD Anderson Cancer Center, Houston (N.L.P.).

13. Department of Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor (S.S.H.).

14. IRD, Sorbonne University, UMMISCO, Bondy, France (E.P.).

15. Sorbonne Université, INSERM NutriOmics, Paris, France (E.P.).

Abstract

BACKGROUND: Immune checkpoint inhibitors (ICIs) are approved for multiple cancers but can result in ICI-associated myocarditis, an infrequent but life-threatening condition. Elevations in cardiac biomarkers, specifically troponin-I (cTnI), troponin-T (cTnT), and creatine kinase (CK), are used for diagnosis. However, the association between temporal elevations of these biomarkers with disease trajectory and outcomes has not been established. METHODS: We analyzed the diagnostic accuracy and prognostic performances of cTnI, cTnT, and CK in patients with ICI myocarditis (n=60) through 1-year follow-up in 2 cardio-oncology units (APHP Sorbonne, Paris, France and Heidelberg, Germany). A total of 1751 (1 cTnT assay type), 920 (4 cTnI assay types), and 1191 CK sampling time points were available. Major adverse cardiomyotoxic events (MACE) were defined as heart failure, ventricular arrhythmia, atrioventricular or sinus block requiring pacemaker, respiratory muscle failure requiring mechanical ventilation, and sudden cardiac death. Diagnostic performance of cTnI and cTnT was also assessed in an international ICI myocarditis registry. RESULTS: Within 72 hours of admission, cTnT, cTnI, and CK were increased compared with upper reference limits (URLs) in 56 of 57 (98%), 37 of 42 ([88%] P =0.03 versus cTnT), and 43 of 57 ([75%] P <0.001 versus cTnT), respectively. This increased rate of positivity for cTnT (93%) versus cTnI ([64%] P <0.001) on admission was confirmed in 87 independent cases from an international registry. In the Franco–German cohort, 24 of 60 (40%) patients developed ≥1 MACE (total, 52; median time to first MACE, 5 [interquartile range, 2–16] days). The highest value of cTnT:URL within the first 72 hours of admission performed best in terms of association with MACE within 90 days (area under the curve, 0.84) than CK:URL (area under the curve, 0.70). A cTnT:URL ≥32 within 72 hours of admission was the best cut-off associated with MACE within 90 days (hazard ratio, 11.1 [95% CI, 3.2–38.0]; P <0.001), after adjustment for age and sex. cTnT was increased in all patients within 72 hours of the first MACE (23 of 23 [100%]), whereas cTnI and CK values were less than the URL in 2 of 19 (11%) and 6 of 22 (27%) of patients ( P <0.001), respectively. CONCLUSIONS: cTnT is associated with MACE and is sensitive for diagnosis and surveillance in patients with ICI myocarditis. A cTnT:URL ratio <32 within 72 hours of diagnosis is associated with a subgroup at low risk for MACE. Potential differences in diagnostic and prognostic performances between cTnT and cTnI as a function of the assays used deserve further evaluation in ICI myocarditis.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3